BMY stock performance?

Bristol-Myers Squibb Co. (BMY) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Bristol-Myers Squibb Co. (BMY) Stock Summary:

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $50.65 USD
Change Today +0.11 / 0.22%
Volume 4.0M
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $57.49
52 Week Low
09/5/13 - $41.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

Novartis Rises Most in Three Years on Heart-Drug Trial
Novartis Heart Failure Drug Tops Standard in Study
Yesterday’s Inversion Buyers Are Next Targets: Real M&A
Bristol-Myers Tops Earnings Estimates on Drug Sales
Patient Cures Spur Demand for $1,000 Hepatitis C Pill

bristol-myers squibb co (BMY) Related News

It's Not Just Disruption: More Management Wisdom You Should Doubt
'Miracle' Data Could Lead to Cancer Cures
Buying Prescription Drugs Online Without Getting Burned
Bid & Ask: The Deals of the Week

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company and Pfizer Inc. Announce Results of Pre-Specified Secondary Analysis of Eliquis Phase 3 AMPLIFY-EXT Trial

Bristol-Myers Squibb Company and Pfizer Inc. announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. This effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT population. These data were presented during an oral session in Barcelona, Spain, at the ESC Congress 2014. AMPLIFY-EXT was a randomized, double-blind, placebo-controlled extended treatment superiority study with 12 months of treatment plus one month follow-up in patients with VTE who completed six to 12 months of anticoagulation therapy. The secondary analysis presented showed that, compared with placebo, Eliquis 2.5 mg (p=0.032) and 5 mg (p=0.004) were both associated with significant reduction in all-cause hospitalization. Of the 2,486 patients included in the AMPLIFY-EXT trial, 138 patients were hospitalized at least once, including 62 (7.48%) in the placebo group (n=829), 42 (5.00%) in the Eliquis 2.5 mg group (n=840), and 34 (4.18%) in the Eliquis 5 mg group (n=813). Of the first hospitalizations in the placebo group, a total of 32 (51.6%) were attributed to VTE recurrence versus six (17.7%) in the Eliquis 5 mg group and 11 (26.2%) in the Eliquis 2.5 mg group. A total of 14 Bristol-Myers Squibb/Pfizer alliance-sponsored abstracts, including the AMPLIFY-EXT pre-specified secondary analysis were accepted for presentation at the ESC Congress 2014.

European Commission Approves Bristol-Myers Squibb's Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the European Union (EU) and will be available for use in combination with other medicinal products, providing a shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. Present approval allows for the marketing of Daklinza in all 28 Member States of the EU. The marketing authorization for Daklinza follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP), a designation that is granted to new medicines of major public health interest. The approval of Daklinza is supported by data from multiple studies, including an open-label, randomized study of Daklinza with sofosbuvir in genotypes 1, 2, and 3, including patients with no response to prior therapy with telaprevir or boceprevir and patients with fibrosis. Results showed that a regimen of Daklinza with sofosbuvir achieved SVR(12) (sustained virologic response 12 weeks after the end of treatment; a functional cure) in 99% of treatment-naïve patients with HCV genotype 1, 100% of patients with genotype 1 who had failed treatment with either telaprevir or boceprevir, 96% of those with genotype 2 and 89% of those with genotype 3.

Bristol-Myers Squibb Company and Pfizer Inc. Announce U.S. Food and Drug Administration Approval of New Drug Application for Eliquis

Bristol-Myers Squibb Company and Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. The full Prescribing Information for Eliquis includes Boxed Warnings for the increased risk of thrombotic events in patients who prematurely discontinue Eliquis and for the increased risk of epidural or spinal hematoma, which may cause long-term or permanent paralysis, in patients using Eliquis and undergoing spinal epidural anesthesia or spinal puncture. The FDA approval of Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy, is based on data from the global AMPLIFY and AMPLIFY-EXT studies. The AMPLIFY study, a randomized, double-blind trial, was designed to demonstrate the efficacy and safety of Eliquis for the treatment of DVT and PE, and included patients with confirmed symptomatic DVT or PE (2,609 for Eliquis and 2,635 for standard of care, which was initial enoxaparin treatment for at least five days, overlapped by warfarin therapy [International Normalized Ratio (INR) range 2.0-3.0] orally for six months). In the AMPLIFY study, Eliquis 10 mg twice daily for one week followed by 5 mg twice daily for six months demonstrated efficacy comparable to standard of care in treating DVT and PE patients for the primary efficacy composite endpoint of recurrent, symptomatic VTE, or VTE-related death (2.3% vs. 2.7%, relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; P-value<0.0001 for noninferiority)>

Bristol-Myers Squibb Co. financial resources

otc, otcbb, pinksheet, BMY, ob Bristol-Myers Squibb Co.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $50.65 USD +0.11

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.28 USD -0.32
Amgen Inc $139.38 USD +0.69
Biogen Idec Inc $343.04 USD +1.80
Eli Lilly & Co $63.56 USD +0.45
Novo Nordisk A/S kr259.30 DKK +0.30

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 31.4x
Price/Sales 5.2x
Price/Book 5.5x
Price/Cash Flow 31.2x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Archieved Financial News About Bristol-Myers Squibb Co.

UK's NICE backs cut-price Novartis leukaemia drug

Read article

Fed Dissenters, Euro Tax, Zynga, Apple, Melanoma: Compliance

Quote: deathsBristol-Myers Squibb Co. (BMY)’s Yervoy, cleared in March as the first treatment proven to extend lives of advanced melanoma patients. Jack ScannellLondonNew York, may earn $1.5 billion from Yervoy in 2015, according to the average estimate of three analysts surveyed by Bloomberg. Whiskey, Wine Fraud on Americans Brings 5-Year Term for Briton A British man who defrauded American and Canadian investors of about 30 million pounds ($49 million) through investment schemes tied to win...
Read article

Roche, Daiichi Sankyo Win U.S. Approval on Drug to Treat Advanced Melanoma

Quote: deathsBaselSwitzerlandBristol-Myers Squibb Co. (BMY)’s Yervoy, cleared in March as the first treatment proven to extend lives of advanced melanoma patients. Richard Pazdur, director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research, said in the statement. “Zelboraf is the second new cancer drug approved that demonstrates an improvement in overall survival.” Jack ScannellLondonNew York, may earn $1.5 billion from Yervoy in 201...
Read article

U.S. FDA approves Roche skin cancer drug Zelboraf

Quote: Zelboraf was developed in partnership with Daiichi Sankyo (4568.T) and is the second drug to be approved for melanoma this year, after Yervoy from Bristol-Myers Squibb(BMY.N). Prior to 2011, the FDA had not approved a new melanoma drug in 13 years. Both are expected to top $1 billion in sales for their manufacturers, and analysts at Sanford Bernstein predict that Yervoy will capture 60 percent of the U.S. market versus 40 percent for Zelboraf. "The FDA's quick action on this drug approval is imp...
Read article

Daiichi, Roche Win U.S. Drug Approval

Quote: In March, the FDA cleared Yervoy from Bristol-Myers Squibb Co. Unlike vemurafenib's focus on the molecular causes of metastatic melanoma, Yervoy works by marshaling the body's immune system to fight the cancer. The rival treatments are expensive, with a course of Yervoy costing $120,000. Most patients will take Zelboraf for about six months at an estimated cost of $56,400, Roche said. The genetic test identifying skin-cancer patients with the BRAF mutation will cost $120-$150, the company said. ...
Read article

Bristol-Myers Squibb Announces the Winners of the 2011 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest

Keywords: Bristol-Myers Squibb Announces the Winners of the 2011 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest, bmy
Read article

Bayer and J&J 'Muddied The Waters' With Xarelto

Quote: Meanwhile, BoehringerIngelheim has already launched Pradaxa with an aggressive promotionalcampaign and Pfizer (PFE) and Bristol-Myers Squibb (BMY) recently released studyresults that has some analysts speculating their apixaban bold thinnerwill be the one to beat (see this). The problem, according to the editorial, is that the Rocket study didnot show any superiority for Xarelto on an “intent-to-treat” basis.Instead, the study authors used a different group of patients - theas-treate...
Read article

Cramer's Battle Plan After Wednesday's Steep Sell-Off

Quote: Specifically, Cramer stated you should wait for VZ to go to at least a 6% yield and that you should wait for a 5% yield on Bristol-Myers Squibb (BMY).Cramer discussed the difference between silver and gold, noting that gold is a purer currency while silver is also an industrial metal, and that he would prefer investors use Gold as their allocation over silver for this distinction. Cramer usually suggests that investors choose the SPDR Gold ETF (GLD) if they want to invest in gold, but also has r...
Read article

A.M. Vitals: Genetic Immunotherapy For Leukemia Holds Promise

Quote: The treatment, to be called Complera, will join on the market another once-daily, three-drug pill intended for people new to HIV therapy — Atriplia, marketed by Gilead in conjunction with Bristol-Myers Squibb. Pet Food Threat: the New York Times’ Well blog reports. Pets can get food poisoning, and humans can get it from coming into contact with tainted pet food. Vets recommend not feeding pets raw food diets and storing dry foods, pet vitamins and treats in a cool, dry place, the NYT...
Read article

Gilead Investors Eye Next Catalyst

Keywords: gilead sciences,hiv,aids,johnson & johnson,j&j,quad,atripla,truvada,edurant,complera,glaxosmithkline,abbott laboratories,norvir,bristol,myers squibb,integrase inhibitors,drug cocktail,viread,emtriva,MARKETS,GILD,JNJ,GSK,BMY,TEVA
Quote: Atripla, marketed with partner Bristol-Myers SquibbBMY), is the subject of a patent challenge from Teva Pharmaceutical IndustriesTEVA). Teva also is challenging Truvada’s patent. the company also announced a resolution to manufacturing problems at a California plant. The Food and Drug Administration warned the company to fix the issues last September. AIDS drugs are expensive (Complera will be sold for about $1,700 a month), and some of the pullback in Gilead’s stock is probably rela...
Read article

FDA Submissions May Make This Bottom Bouncer More Appealing

Quote: Erbitux is marketed in the United States by Bristol-Myers Squibb Company (BMY) and Eli Lilly and Company (LLY). Merck KGaA (MRK) has the right to market Erbitux outside the US and Canada. Qiagen N.V is a provider of sample and assay technologies for life sciences, molecular diagnostics, applied testing and pharma. Its Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. The company's assay technologies are used to make specific target biomolecules, such as t...
Read article

Qiagen: FDA Submissions May Make This Bottom Bouncer More Appealing

Quote: Erbitux is marketed in the United States by Bristol-Myers Squibb Company (BMY) and Eli Lilly and Company (LLY). Merck KGaA (MRK) has the right to market Erbitux outside the US and Canada. Qiagen N.V is a provider of sample and assay technologies for life sciences, molecular diagnostics, applied testing and pharma. Its Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. The company's assay technologies are used to make specific target biomolecules, such as t...
Read article

AMRI cuts net loss to $568K

Quote: In the year-ago quarter, AMRI (Nasdaq: AMRI) reported a net loss of $3.9 million, or 13 cents a share. Total revenue for the second quarter was $52.4 million, a 9 percent increase from a year ago. Bristol-Myers SquibbBristol-Myers SquibbLatest from The Business JournalsGenetic testing for cholesterol drug Plavix could push Harmonyx to double revenuePlavix heart drug priced higher than local roots' rival’sBiochemical payoffFollow this company. Thomas D’Ambra, CEO of AMRI, attributed...
Read article

Stock Market Bargains Go Begging: Cramer

Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading,, Jim Cramer ,Investing Opinion
Quote: The futures themselves have long since ceased to be an accurate barometer of the market and are instead accurate barometers of hedge-fund allocations to the commodity.It is tremendously beneficial to the oil companies, particularly those that are refiners, to keep it that way, so they don't bring oil to the market to respond to the demand.It's a big act.But it does affect the consumer.If Standard & Poor's hadn't been like Zeus throwing thunderbolts at our markets -- and if there weren't genuine ...
Read article

A.M. Vitals: Alzheimer's Research Suggests Early Interventions

Quote: That’s why Pfizer, Johnson & Johnson and Bristol-Myers Squibb are looking to treat patients with signs of milder memory loss, the paper says. Hackable Devices:the Associated Press reports. Many devices contain wireless chips, but most are too small to contain encryption technology, the AP says. Lab-Grown Sperm: the WSJ reports. Experts call the research, published in Cell, a breakthrough but caution it may not translate to humans. Lower Costs: the Los Angeles Times reports. Increased u...
Read article

Qiagen completes 2nd U.S. FDA submission of therascreen KRAS RGQ PCR Kit

Quote: by Bristol-Myers Squibb (BMY) and Eli Lilly (LLY). Merck KGaA has the right to market Erbitux outside the U.S. and Canada. QIAGEN submitted a Premarket Approval, or PMA, application to the FDA for use of its innovative assay in determining which patients can be expected to benefit from Erbitux in treatment of mCRC. PMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancer. FDA decisions are expected in 2012.
Read article

UPDATE 3-Deutsche Post upbeat after strong Q2

Keywords: Britain, China, France, Germany, India, Scotland, United States, David Cowell, DAX 30
Read article

UPDATE 1-Bristol-Myers gets FDA ok for subcutaneous Orencia

Keywords: United States, CarolBishopric
Read article

UPDATE 1-Bristol-Myers sales eclipse forecast

Keywords: United States, John Wallace
Quote: forecast of $0.55 * Raises 2011 profit view to $2.20 to $2.30/shr * Affirms 2013 forecast, representing fairly stable profit (Adds product sales, 2011, 2013 forecasts) NEW YORK, July 28 (Reuters) - Bristol-Myers Squibb Co's (BMY.N) second-quarter sales blew past Wall Street forecasts, but sharply higher taxes kept earnings roughly in line with expectations. The U.S. drugmaker on Thursday raised its 2011 profit view and reaffirmed a 2013 forecast that suggests relatively stable earnings that year...
Read article

Gold Moves Higher As Silver Slides Ahead Of Debt Ceiling Vote

Quote: Ahead of the bell, drug maker Bristol-Myers Squibb (BMY) raised its 2011 profit forecast after second-quarter sales of nine of its 10 top drugs exceeded analysts’ estimates. Also, Exxon Mobil (XOM) reported its highest quarterly profit since the third-quarter of 2008. But the results fell short of Wall Street estimates. Data from the National Association of Realtors is scheduled to be released at 10 a.m. eastern time for previously owned home sales in June.......
Read article

You can still leave a comment about Bristol-Myers Squibb Co. BMY

Besides Bristol-Myers Squibb Co.'s Stock there is more great Microcap and Stock Market information available at